Miocardiopatía dilatada

  1. García Campos, A. 1
  2. Pérez Domínguez, M. 1
  3. Díaz Fernández, B. 1
  4. González Juanety, J.R. 1
  1. 1 Servicio de Cardiología. Hospital Clínico Universitario de Santiago de Compostela. Santiago de Compostela. La Coruña. España. CIBERCV
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Ano de publicación: 2021

Título do exemplar: Enfermedades cardiovasculares (VIII)

Serie: 13

Número: 42

Páxinas: 2447-2458

Tipo: Artigo

DOI: 10.1016/J.MED.2021.09.021 DIALNET GOOGLE SCHOLAR

Outras publicacións en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumo

Dilated cardiomyopathy is defined by presence of left ventricular or biventricular dilation and left systolic dysfunction in absence of hypertension, coronary disease, or valvular disease that would justify it. Its causes can be divided into two large groups: those of genetic origin and those of nongenetic origin, which include infectious, toxic, and autoimmune disease causes, among others. Its natural course varies significantly based on the different etiologies and its diagnosis can influence the disease's management and prognosis. In this article, we will review the different dilated cardiomyopathy etiologies, the imaging and genetic techniques that allow for diagnosing it, the prognosis of the disease, and therapeutic options.

Referencias bibliográficas

  • Akinrinade O, Koskenvuo JW, Alastalo T-P. Prevalence of titin truncating variants in general population. PLoS One. 2015;10(12):e0145284.
  • Aleksova A, Carriere C, Zecchin M, Barbati G, Vitrella G, Di Lenarda A. New onset left bundle branch block independently predicts long term mortality in patients with idiopathic dilated cardiomyopathy: data from the Trieste Heart Muscle Disease Registry. Europace. 2014;16(10): 1450-9.
  • Anderson L. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22(23): 2171-9.
  • Anderson L, Pennell D. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the Eu-ropean Society of Cardiology. Eur Heart J. 2008;29(13):1696.
  • Anguita M, Bayés-Genís A, Cepeda JM, Cinza S, Cosín J, Leiro MC. Consenso de expertos sobre la insuficiencia cardiaca con fracción de eyección reducida: más allá de las guías. Rev Esp Cardiol Supl. 2020;20: 1-46.
  • Assomull RG, Shakespeare C, Kalra PR, Lloyd G, Gulati A, Strange J. Role of cardiovascular magnetic resonance as a gatekeeper to invasive coronary angiography in patients presenting with heart failure of unknown etiology. Circulation. 2011;124(12):1351-60.
  • Bauersachs J, König T, Meer P, Petrie MC, Hilfiker‐Kleiner D, Mbakwem A. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail. 2019;21(7):827-43.
  • Becker MAJ, Cornel JH, van de Ven PM, van Rossum AC, Allaart CP, Germans T. The prognostic value of late gadolinium enhanced cardiac magnetic resonance imaging in nonischemic dilated cardiomyopathy. JACC Cardiovasc Imaging. 2018;11(9):1274-84.
  • Begay RL, Graw SL, Sinagra G, Asimaki A, Rowland TJ, Slavov DB. Filamin C truncation mutations are associated with arrhythmogenic dilated cardiomyopathy and changes in the cell : cell adhesion structures. JACC Clin Electrophysiol. 2018;4(4):504-14.
  • Birnie DH, Nery PB, Ha AC, Beanlands RSB. Cardiac sarcoidosis. J Am Coll Cardiol. 2016;68(4):411-21.
  • Bozkurt B, Colvin M, Cook J, Cooper LT, Deswal A, Fonarow GC. Current diagnostic and treatment strategies for specific dilated cardiomyopathies: A scientific statement from the american heart association. Circulation. 2016;134(23):e579-e646.
  • Cannatà A, Fabris E, Merlo M, Artico J, Gentile P, Pio Loco C. Sex differences in the long term prognosis of dilated cardiomyopathy. Can J Cardiol. 2020;36(1):37-44.
  • Codd MB, Sugrue DD, Gersh BJ, Melton LJ. Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population based study in Olmsted County, Minnesota, 1975-1984. Circulation. 1989;80(3):564-72.
  • Cooper LT. Myocarditis. N Engl J Med. 2009;360(15):1526-38.
  • Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2): 171-90.
  • Donal E, Delgado V, Bucciarelli-Ducci C, Galli E, Haugaa KH, Charron P. Multimodality imaging in the diagnosis, risk stratification, and management of patients with dilated cardiomyopathies: an expert consensus document from the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2019;20(10):1075-93.
  • Dries DL, Exner DV, Gersh BJ, Cooper HA, Carson PE, Domanski MJ. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med. 1999;340(8):609-16.
  • Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P. Classification of the cardiomyopathies: a position statement from the european society of cardiology working group on myocardial and pericardial diseases. Eur Heart J. 2007;29(2):270-6.
  • Faris RF, Henein MY, Coats AJS. Influence of gender and reported alcohol intake on mortality in nonischemic dilated cardiomyopathy. Heart Dis. 2003;5(2):89-94.
  • George A, Figueredo VM. Alcoholic cardiomyopathy: A review. J Card Fail. 2011;17(10):844-9.
  • Gil KE, Pawlak A, Gil RJ, Frontczak-Baniewicz M, Bil J. The role of invasive diagnostics and its impact on the treatment of dilated cardiomyopathy: A systematic review. Adv Med Sci. 2016;61(2):331-43.
  • Gulati A, Jabbour A, Ismail TF, Guha K, Khwaja J, Raza S. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA. 2013; 309(9):896.
  • Haas J, Frese KS, Peil B, Kloos W, Keller A, Nietsch R. Atlas of the clinical genetics of human dilated cardiomyopathy. Eur Heart J. 2015;36(18):1123-35.
  • Halliday BP, Gulati A, Ali A, Newsome S, Lota A, Tayal U. Sex and age based differences in the natural history and outcome of dilated cardiomyopathy: Sex and age based differences in DCM. Eur J Heart Fail. 2018;20(10):1392-400.
  • Halliday BP, Wassall R, Lota AS, Khalique Z, Gregson J, Newsome S. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open label, pilot, randomised trial. The Lancet. 2019;393(10166):61-73.
  • Halliday BP, Gulati A, Ali A, Guha K, Newsome S, Arzanauskaite M. Association between midwall late gadolinium enhancement and sudden cardiac death in patients with dilated cardiomyopathy and mild and moderate left ventricular systolic dysfunction. Circulation. 2017;135(22): 2106-15.
  • Herman DS, Lam L, Taylor MRG, Wang L, Teekakirikul P, Christodoulou D. Truncations of titin causing dilated cardiom-yopathy. N Engl J Med. 2012;366(7):619-28.
  • Hershberger RE, Givertz MM, Ho CY, Judge DP, Kantor PF, McBride KL. Genetic evaluation of cardiomyopathy : A Heart Failure Society of America Practice Guideline. J Card Fail. 2018;24(5):281-302.
  • Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat Rev Cardiol. 2013;10(9):531-47.
  • Huizar JF, Ellenbogen KA, Tan AY, Kaszala K. Arrhythmia Induced Cardiomyopathy. J Am Coll Cardiol. 2019;73(18):2328-44.
  • Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, López VA. Myocardial Iodine-123 metaIodobenzylguanidine imaging and cardiac events in heart failure. J Am Coll Cardiol. 2010;55(20):2212-21.
  • Japp AG, Gulati A, Cook SA, Cowie MR, Prasad SK. The diagnosis and evaluation of dilated cardiomyopathy. J Am Coll Cardiol. 2016;67(25): 2996-3010.
  • Jefferies JL, Towbin JA. Dilated cardiomyopathy. The Lancet. 2010; 375(9716):752-62.
  • Kamperidis V, van Wijngaarden SE, van Rosendael PJ, Kong WKF, Regeer MV, van der Kley F. Mitral valve repair for secondary mitral regurgitation in non ischaemic dilated cardiomyopathy is associated with left ventricular reverse remodelling and increase of forward flow. Eur Heart J Cardiovasc Imaging. 2018;19(2):208-15.
  • Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016;375(13):1221-30.
  • Kumar S, Baldinger SH, Gandjbakhch E, Maury P, Sellal J-M, Androulakis AFA. Long term arrhythmic and nonarrhythmic outcomes of lamin A/C mutation carriers. J Am Coll Cardiol. 2016;68(21):2299-307.
  • Lamounier Júnior A, Ferrari F, Max R, Ritt LEF, Stein R. Importance of genetic testing in dilated cardiomyopathy: Applications and challenges in clinical practice. Arq Bras Cardiol. 2019;113(2):274-81.
  • Lund LH, Edwards LB, Dipchand AI, Goldfarb S, Kucheryavaya AY, Levvey BJ. The registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Heart Transplantation Report:2016; Focus theme: Primary diagnostic indications for transplant. J Heart Lung Transplant. 2016;35(10):1158-69.
  • Mahrholdt H, Wagner A, Judd RM, Sechtem U, Kim RJ. Delayed enhancement cardiovascular magnetic resonance assessment of non ischaemic cardiomyopathies. Eur Heart J. 2005;26(15): 1461-74.
  • Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D. Contemporary definitions and classification of the cardiomyopathies: An American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemio-logy and Prevention. Circulation. 2006;113(14): 1807-16.
  • Masci PG, Schuurman R, Andrea B, Ripoli A, Coceani M, Chiappino S. Myocardial fibrosis as a key determinant of left ventricular remodeling in idiopathic dilated cardiomyopathy: A contrast-enhanced cardiovascular magnetic study. Circ Cardiovasc Imaging. 2013;6(5):790-9.
  • McNamara DM, Starling RC, Cooper LT, Boehmer JP, Mather PJ, Janosko KM. Clinical and demographic predictors of outcomes in recent onset dilated cardiomyopathy. J Am Coll Cardiol. 2011;58(11):1112-8.
  • Merlo M, Gobbo M, Stolfo D, Losurdo P, Ramani F, Barbati G. The prognostic impact of the evolution of RV function in idiopathic DCM. JACC Cardiovasc Imaging. 2016;9(9):1034-42.
  • Merlo M, Pyxaras SA, Pinamonti B, Barbati G, Di Lenarda A, Sinagra G. Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment. J Am Coll Cardiol. 2011;57(13):1468-76.
  • Merlo M, Pivetta A, Pinamonti B, Stolfo D, Zecchin M, Barbati G. Long term prognostic impact of therapeutic strategies in patients with idiopathic dilated cardiomyopathy: changing mortality over the last 30 years: Prognosis of idiopathic dilated cardiomyopathy. Eur J Heart Fail. 2014;16(3):317-24.
  • Merlo M, Cannatà A, Gobbo M, Stolfo D, Elliott PM, Sinagra G. Evolving concepts in dilated cardiomyopathy: Evolving concepts in DCM. Eur J Heart Fail. 2018;20(2):228-39.
  • Mitropoulou P, Georgiopoulos G, Figliozzi S, Klettas D, Nicoli F, Masci PG. Multimodality imaging in dilated cardiomyopathy: With a focus on the role of cardiac magnetic resonance. Front Cardiovasc Med. 2020;7:97.
  • Nugent AW, Chondros P, Carlin JB, Wilkinson LC, Chow CW, Weintraub RG. The epidemiology of childhood cardiomyopathy in Australia. N Engl J Med. 2003;348(17):1639-46.
  • Obadia J-F, Messika-Zeitoun D, Leurent G, Iung B, Bonnet G, Piriou N. Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation. N Engl J Med. 2018;379(24):2297-306.
  • Park S-M, Park SW, Casaclang-Verzosa G, Ommen SR, Pellikka PA, Miller FA. Diastolic dysfunction and left atrial enlargement as contributing factors to functional mitral regurgitation in dilated cardiomyopathy: Data from the Acorn trial. Am Heart J. 2009;157(4):762.e3-762.e10.
  • Patel AR, Kramer CM. Role of cardiac magnetic resonance in the diagnosis and prognosis of nonischemic cardiomyopathy. JACC Cardiovasc Imaging. 2017;10(10):1180-93.
  • Peña-Peña ML, Monserrat L. Papel de la genética en la estratificación del riesgo de pacientes con miocardiopatía dilatada no isquémica. Rev Esp Cardiol. 2019;72(4):333-40.
  • Piano MR. Alcoholic cardiomyopathy. Chest. 2002;121(5):1638-50.
  • Pinto YM, Elliott PM, Arbustini E, Adler Y, Anastasakis A, Böhm M. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2016;37(23):1850-8.
  • Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-200.
  • Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36(41):2793-867.
  • Rakar S, Sinagra G, Di Lenarda A, Poletti A, Bussani R, Silvestri F. Epidemiology of dilated cardiomyopathy: A prospective postmortem study of 5252 necropsies. Eur Heart J. 1997;18(1):117-23.
  • Rapezzi C, Arbustini E, Caforio ALP, Charron P, Gimeno-Blanes J, Helio T. Diagnostic work up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34(19):1448-58.
  • Reichart D, Magnussen C, Zeller T, Blankenberg S. Dilated cardiomyopathy: from epidemiologic to genetic phenotypes: A translational review of current literature. J Intern Med. 2019;286(4):362-72.
  • Roger VL. Epidemiology of heart failure. Circ Res. 2013;113(6):646-59.
  • Rosenbaum AN, Agre KE, Pereira NL. Genetics of dilated cardiomyo-pathy: practical implications for heart failure management. Nat Rev Cardiol. 2020;17(5):286-97.
  • Rossi A, Dini FL, Faggiano P, Agricola E, Cicoira M, Frattini S. Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non ischaemic dilated cardiomyopathy. Heart. 2011; 97(20): 1675-80.
  • Seferovic PM, Polovina M, Bauersachs J, Arad M, Gal TB, Lund LH. Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21(5):553-76.
  • Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM. Transcatheter Mitral Valve Repair in Patients with Heart Failure. N Engl J Med. 2018;379(24):2307-18.
  • Verdonschot JAJ, Merken JJ, Brunner-La Rocca H-P, Hazebroek MR, Eurlings CGMJ, Thijssen E. Value of speckle tracking : based deformation analysis in screening relatives of patients with asymptomatic dila-ted cardiomyopathy. JACC Cardiovasc Imaging. 2020;13(2):549-58.
  • Weintraub RG, Semsarian C, Macdonald P. Dilated cardiomyopathy. The Lancet. 2017;390(10092):400-14.
Fonte de datos: Dialnet